|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2540-2544.
Prepublished online as a Blood First Edition Paper on July 11, 2006; DOI 10.1182/blood-2006-03-013193.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Catherine Sebban,
Nicolas Mounier,
Nicole Brousse,
Coralie Belanger,
Pauline Brice,
Corinne Haioun,
Herve Tilly,
Pierre Feugier,
Redah Bouabdallah,
Chantal Doyen,
Gilles Salles, and
Bertrand Coiffier
From the Departments of Hematology of Centre Léon Bérard, Lyon, France; Hôpital Saint-Louis, Paris, France; Hôpital Necker, Paris, France; Centre Hospitalo-Universitaire (CHU) Henri Mondor, Créteil, France; Centre Becquerel, Rouen, France; CHU de Brabois, Vandoeuvre les Nancy, France; Institut Paoli Calmette, Marseille, France; Université Catholique de Louvain, Yvoir, Belgium; and Hospices Civils de Lyon, Pierre Bénite, France.
The purpose of this study is to compare our standard chemotherapy regimen (CHVP [cyclophosphamide, doxorubicin, teniposide, and prednisone]) plus interferon with 4 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by high-dose therapy with autologous stem cell transplantation (ASCT) in treatment-naive patients with advanced follicular lymphoma. Four hundred one patients were included from July 1994 to March 2001: 209 received 12 cycles of CHVP plus interferon  for 18 months (CHVP-I arm) and 192 received 4 cycles of CHOP followed by high-dose therapy (HDT) with total body irradiation and ASCT (CHOP-HDT arm). Overall response rates were similar in both groups (79% and 78% after induction chemotherapy, respectively). One hundred thirty-one of the 150 patients eligible for HDT underwent transplantation (87%). Intent-to-treat analysis after a median follow-up of 7.5 years showed that there was no difference between the 2 arms for overall survival (P = .53) or event-free survival (P = .11). Patients with a complete response at the end of the induction therapy had a statistically longer event-free survival and overall survival (P = .02 and < .001, respectively). After long-term follow-up, our study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma. High-dose therapy should be reserved for relapsing patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Autologous transplantation for follicular lymphoma? Not too soon!
- Koen van Besien
Blood 2006 108: 2496-2497.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
Y. L. Kasamon, R. J. Jones, R. A. Brodsky, E. J. Fuchs, W. Matsui, L. Luznik, J. D. Powell, A. L. Blackford, A. Goodrich, C. D. Gocke, et al.
Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
Ann. Onc.,
October 30, 2009;
(2009)
mdp484v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye
Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence
Oncologist,
October 1, 2009;
14(suppl_2):
17 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gisselbrecht, J. Vose, A. Nademanee, A. M. Gianni, and A. Nagler
Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response
Oncologist,
October 1, 2009;
14(suppl_2):
41 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bischof Delaloye, P. S. Conti, C. Gisselbrecht, and S. A. Gregory
Summary
Oncologist,
October 1, 2009;
14(suppl_2):
52 - 54.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Moskowitz and C. H. Moskowitz
Controversies in the Treatment of Lymphoma with Autologous Transplantation
Oncologist,
September 1, 2009;
14(9):
921 - 929.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Foster, D. A. Gabriel, and T. Shea
Role of Hematopoietic Stem Cell Transplant in the Management of Follicular Lymphoma
Oncologist,
July 1, 2009;
14(7):
726 - 738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kornacker, J. Stumm, C. Pott, S. Dietrich, S. Sussmilch, M. Hensel, M. Nickelsen, M. Witzens-Harig, M. Kneba, N. Schmitz, et al.
Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up
Ann. Onc.,
April 1, 2009;
20(4):
722 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Gyan, C. Foussard, P. Bertrand, P. Michenet, S. Le Gouill, C. Berthou, H. Maisonneuve, V. Delwail, R. Gressin, P. Quittet, et al.
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years
Blood,
January 29, 2009;
113(5):
995 - 1001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Salles, N. Mounier, S. de Guibert, F. Morschhauser, C. Doyen, J.-F. Rossi, C. Haioun, P. Brice, B. Mahe, R. Bouabdallah, et al.
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Blood,
December 15, 2008;
112(13):
4824 - 4831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, J. Radford, A. Van Hoof, U. Vitolo, P. Soubeyran, H. Tilly, P. C. Huijgens, A. Kolstad, F. d'Amore, M. G. Diaz, et al.
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
J. Clin. Oncol.,
November 10, 2008;
26(32):
5156 - 5164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin,
September 1, 2008;
58(5):
305 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sebban, P. Brice, R. Delarue, C. Haioun, B. Souleau, N. Mounier, N. Brousse, P. Feugier, H. Tilly, P. Solal-Celigny, et al.
Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study
J. Clin. Oncol.,
July 20, 2008;
26(21):
3614 - 3620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Appelbaum
Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma: Yesterday, Today, and Tomorrow
J. Clin. Oncol.,
June 20, 2008;
26(18):
2927 - 2929.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Plastaras, E. Glatstein, and S. J. Schuster
Commentary: Let the Tail Wag the Dog: The Case for Radioimmunotherapy of Low-Grade Follicular Lymphoma
Oncologist,
June 1, 2008;
13(6):
655 - 656.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist,
June 1, 2008;
13(6):
657 - 667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ladetto, F. De Marco, F. Benedetti, U. Vitolo, C. Patti, A. Rambaldi, A. Pulsoni, M. Musso, A. M. Liberati, A. Olivieri, et al.
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Blood,
April 15, 2008;
111(8):
4004 - 4013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Weingart, F. A. Rehan, H. Schulz, F. Naumann, I. Knauel, C. B. J. Bohlius, and A. Engert
Sixth Biannual Report of the Cochrane Haematological Malignancies Group Focus on Non-Hodgkin Lymphoma
J Natl Cancer Inst,
September 5, 2007;
99(17):
E1 - E1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Carlotti, G. A. Palumbo, E. Oldani, D. Tibullo, S. Salmoiraghi, A. Rossi, J. Golay, A. Pulsoni, R. Foa, and A. Rambaldi
Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Haematologica,
August 1, 2007;
92(8):
1127 - 1130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman
Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up
J. Clin. Oncol.,
June 20, 2007;
25(18):
2554 - 2559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Vigouroux, M. Michallet, R. Porcher, M. Attal, L. Ades, M. Bernard, D. Blaise, R. Tabrizi, F. Garban, J.-P. Cassuto, et al.
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
Haematologica,
May 1, 2007;
92(5):
627 - 634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma
J. Clin. Oncol.,
April 10, 2007;
25(11):
1396 - 1402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
